Community Research and Development Information Service - CORDIS

New Research Project Hypo-RESOLVE Investigates Hypoglycaemia and its Impact in Diabetes

Contributed by: Eurice - European Research and Project Office GmbH

Within the newly started European research project Hypo-RESOLVE, 23 leading international players from academia, industry and civil society have joined forces to find better solutions to alleviate the burden and consequences of hypoglycaemia in diabetes. The international consortium aims to provide evidence-based classification of hypoglycaemia to achieve better treatments for people living with diabetes. Diabetes is a global pandemic, currently affecting around 60 million people in Europe.
New Research Project Hypo-RESOLVE Investigates Hypoglycaemia and its Impact in Diabetes
Hypoglycaemia is a common and serious complication of diabetes, particularly affecting people with diabetes on insulin therapy. Consisting of very low levels of blood glucose, hypoglycaemia can lead to cognitive decline, cardiovascular events and even death.

As much about hypoglycaemia remains unknown, the recently started European research project Hypo-RESOLVE (Hypoglycaemia – Redefining SOLutions for better liVEs) aims to provide researchers and clinicians with more validated data about the condition by:
• Creating a sustainable clinical database;
• Conducting studies to better understand the underlying mechanisms of hypoglycaemia;
• Conducting a series of statistical analyses to define predictors and consequences of hypoglycaemia;
• Calculating the financial cost in European countries.

“Our mission within Hypo-RESOLVE is to provide an evidence-based classification of hypoglycaemia based on secure data from 100 to 150 recently conducted clinical trials,” explained Dr Bastiaan de Galan, coordinator of Hypo-RESOLVE and internist at the department of Internal Medicine, Radboud university medical center, in the Netherlands. “With this statistical power, we will be able to make valid statements about the glucose thresholds below which hypoglycaemia constitutes a great risk for people living with diabetes.”

Dr Stephen Gough, Global Chief Medical Officer at Novo Nordisk in Denmark and Hypo-RESOLVE project leader added: “This consortium brings together world leaders from the field of diabetes to reduce the burden of hypoglycaemia. Hypo-RESOLVE paves the way for further research on glucose-lowering interventions that will serve people living with diabetes, clinicians and healthcare companies.”

The voices of people living with diabetes will be at the heart of Hypo-RESOLVE, through the establishment of a Patient Advisory Committee. It will ensure that patients’ insights, opinions and wishes are taken into account across all the multiple components of the project.

“Hypoglycaemia presents a huge psychological burden for people with diabetes. We believe that the Patient Advisory Committee will help contribute to a better understanding of the disease’s impact on people with diabetes and ultimately help improve their lives,” said Prof. Nam H. Cho, President of the International Diabetes Federation (IDF). “Through this project, we also hope to strengthen public awareness of hypoglycaemia and diabetes generally.”

Hypo-RESOLVE is supported with funding of € 26.8 million from the Innovative Medicines Initiative (IMI), a joint undertaking of the European Commission and the European Federation of Pharmaceutical Industries and Associations (EFPIA), the JDRF, and the Leona M. and Harry B. Helmsley Charitable Trust.

The project will officially kick off its activities with a first meeting in Denmark on May 16-17, 2018.

Hypo-RESOLVE Partners at a glance

Austria
Medizinische Universität Graz

Belgium
International Diabetes Federation

Denmark
Nordsjællands University Hospital Hillerød
Novo Nordisk A/S
Syddansk Universitet

France
Centre Hospitalier Universitaire Montpellier

Germany
Eurice – European Research and Project Office GmbH (Project Management)
Sanofi-Aventis Deutschland GmbH

Italy
Universita Degli Studi di Padova

Netherlands
Radboud university medical center (RUMC) / Stichting Katholieke Universiteit (Coordination)

Switzerland
Medtronic International Trading Sarl
SIB Swiss Institute of Bioinformatics
Université de Lausanne

United Kingdom
Eli Lilly and Company Limited
King’s College London
The Chancellor, Masters and Scholars of the University of Cambridge
The University of Edinburgh
The University of Sheffield
University of Dundee

United States
Abbott
JDRF International
The Leona M. and Harry B. Helmsley Charitable Trust
T1D Exchange

Project Coordinator:
Dr Bastiaan de Galan
Radboud university medical center / Stichting Katholieke Universiteit
Phone: +31 243618819
bastiaan.degalan@radboudumc.nl
www.hypo-resolve.eu

Contributor

Organisation

    Eurice - European Research and Project Office GmbH
    Germany
    Website

Related information

Programmes

Countries (10)

  • Austria, Belgium, Switzerland, Germany, Denmark, France, Italy, Netherlands, United Kingdom, United States

Keywords

Diabetes, Hypoglycaemia, IMI, Medical Treatment, Clinical Trial
Follow us on: RSS Facebook Twitter YouTube Managed by the EU Publications Office Top